Global Perspectives: Current and Future Management of Breast Cancer

Practice changes and a look to the future from ESMO 2022 and beyond in triple-negative breast cancer, HR+, HER2– early and metastatic breast cancer.

September 19 and 21, 2022
Nadia Harbeck

FACULTY CO-CHAIR

Nadia Harbeck, MD, PhD

Ludwig-Maximilians-University of Munich – Breast Center, Germany

FACULTY CO-CHAIR

Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Faculty Members

Mark Pegram, MD
Stanford Womens Cancer Center

Hope Rugo, MD, FASCO
University of California San Francisco Comprehensive Cancer Center

William Gradishar, MD
Northwestern Medical Group

Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center

Guy Jerusalem, MD, PhD
University of Liège

Javier Cortes, MD, PhD
Vall d’Hebron University Hospital

Valentina Guarneri, MD, PhD
University of Padua

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Current and Emerging Biomarkers and Testing Methodologies in BC
  • Current and New Treatments in HER2+ Early BC
  • Advances in HER2+ Metastatic Breast Cancer (mBC)
  • Current and Emerging Approaches in HR+, HER2– Early BC
  • Therapeutic Horizons in HR+, HER2– mBC
  • Maximizing Potential Targeting of HER2 in HER2-Low mBC
  • Advances in Early and Metastatic Triple-Negative Breast Cancer (TNBC)

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.